Cervical cancer primary prevention

Cervical cancer Microchapters
Home
Patient Information
Overview
Historical Perspective
Classification
Pathophysiology
Causes
Differentiating Cervical Cancer from other Diseases
Epidemiology and Demographics
Risk Factors
Screening
Natural History, Complications and Prognosis
Diagnosis
Diagnostic Study of Choice
History and Symptoms
Physical Examination
Laboratory Findings
Chest X Ray
CT
MRI
Ultrasound
Other Diagnostic Studies
Treatment
Medical Therapy
Surgery
Cervical Cancer During Pregnancy
Primary Prevention
Secondary Prevention
Cost-Effectiveness of Therapy
Future or Investigational Therapies
Case Studies
Case #1
Cervical cancer primary prevention On the Web
Most recent articles
Most cited articles
Review articles
CME Programs
Powerpoint slides
Images
American Roentgen Ray Society Images of Cervical cancer primary prevention All Images X-rays Echo & Ultrasound CT Images MRI
Ongoing Trials at Clinical Trials.gov
US National Guidelines Clearinghouse
NICE Guidance
FDA on Cervical cancer primary prevention
CDC on Cervical cancer primary prevention
Cervical cancer primary prevention in the news
Blogs on Cervical cancer primary prevention
Directions to Hospitals Treating Cervical cancer
Risk calculators and risk factors for Cervical cancer primary prevention

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]Associate Editor(s)-in-Chief: Nima Nasiri, M.D.[2]

Overview

Most effective and cost efficient primary prevention available for cervical cancer is vaccination against high risk strains of human papilloma virus, which are HPV 16 and 18 and is given to adoloscent and young women ideally before the sexual debut.

Primary Prevention

Primary prevention method for cervical cancer is vaccination against HPV types 16 and 18, there are two type of FDA approved vaccines available in the market. These vaccines are most effective when it's given to women age 9 to 26 and young male population through age 21 according to CDC recommendation.

• HPV vaccine also is recommended for following target population:
  • Young homosexual or bisexual men who have sex with men through age 26
  • HIV infected young adult who have weakened immune system through age 26
  • Young adults who are transgender through age 26

• The trade name of the available FDA approved vaccines include:
  • Gardasil, quadrivalent vaccine, composed of HPV 6, 11, 16 and 18.
  • Cervarix, bivalent vaccine, composed of HPV 16 and 18.